Skip to content Skip to navigation

Academic Events

FEN1 Plays an Important Role in the Development of Anticancer Therapeutics

A novel strategy of drug resistance in tumor progression has been revealed by Zhigang Guo's team (Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University), and the result was published on April.10, 2017.

 

Chemotherapy is one of the most important treatments of cancer. However, the therapeutic effect of chemotherapy is limited due to the resistance of cancer cells, which remains a challenge in cancer therapeutics. As a result, there is a great value to reveal the mechanism of tumor resistance, discover brand-new anticancer therapeutic drugs, optimize of cancer treatments, extend lifespan and promoting quality of life.

Recently, the team led by Zhigang guo, professor of biochemistry and molecular biology at School of Life Sciences of NNU , has revealed the above mechanism. In their study, they found chemotherapy drugs induced the expression of DNA repair enzyme in tumor cells, promoted DNA repair systems, and thus led to the resistance of cancer cells. Further research proved that suppression the progress of DNA repair pathway deferred the generation of tumor resistance efficiently and extended lifespan. Related research findings have been verified on lung cancer and esophagus cancer and papers entitled as “FEN1 promotes tumor progression and confers cisplatin resistance in non-smallcell lung cancer” and” Telomerase antagonist imetelstat increases radiation sensitivityin esophageal squamous cell carcinoma” were published on Molecular Oncology (2017 Mar 29. doi: 10.1002/1878-0261.12058., 5-Year IF=6.3) and Oncotarget (2017, Vol. 8, pp: 13600-13611, 5-Year IF=6.0) respectively.
These findings draw international researchers’ attention deeply and the paper entitled as “Interacting partners of FEN1 and its role in the development of anticancer therapeutics” were published on Oncotarget (2017 Feb 7. doi: 10.18632/oncotarget.15176.) in the form of review.

The first authors (or co-first authors) of the above-mentioned three papers are Dr. Lingfeng He, Dr. Jing Zhang and Dr. Chandra sekharKathera, respectively. The work was supported by The Second Hospital of Nanjing, Jiangsu Cancer Hospial, Shanghai Renji Hospital and Changzhou No.7 People’s Hospital.